IP Library › Granted Patent US 12,576,101
Granted Patent B2
US 12,576,101 · App. 18/677,546 · Granted Mar 17, 2026

Application based nucleotides of

Inventors: Wan-Hua Tsai (Kaohsiung City, TW); Yi-Ting Fang (Tainan City, TW); Chia-Yu Chang (Tainan City, TW); Hsueh-Te Lee (Kaohsiung City, TW)
Assignee: GenMont Biotech Incorporation
A61K31/713A61K35/747A61P3/06C12N1/20C12N15/113C12R2001/225
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,576,101
App. No.
18/677,546
Granted
Mar 17, 2026
Kind
B2
Abstract

An application based on nucleotide fragments of Lactobacillus rhamnosus GM-020, to prepare a composition for anti-lipogenesis. The Lactobacillus rhamnosus GM-020 was deposited on Dec. 18, 2003 and has the CCTCC designation number CCTCC M203098. Also provided is a composition containing Lactobacillus rhamnosus GM-020 or nucleotide fragments thereof as effective ingredients for anti-lipogenesis.

Claims (3)

1 . A method of preparing a pharmaceutical composition comprising adding SEQ ID No. and/or and SEQ ID No. 5 to a composition comprising a pharmaceutical excipient and/or a pharmaceutical vehicle.

2 . A method of inhibiting lipid droplet formation in adipocytes in vitro comprising the administration of a composition comprising SEQ ID No. 1 and/or SEQ ID No. 5.

3 . A method of inhibiting the expression of fatty acid synthase (FAS) in adipocytes in vitro comprising the administration of a composition comprising SEQ ID No. 1 and/or SEQ ID No. 5.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 14, 2024
From: TSAI, WAN-HUA; FANG, YI-TING; CHANG, CHIA-YU; LEE, HSUEH-TE
To: GENMONT BIOTECH INCORPORATION
Reel/Frame 067734/0107 →
Priority Claims (1)
TW 113104601 · Feb 6, 2024 · national
Continuity (1)
Related Publication 20250249028A1 · Aug 7, 2025
References Cited (3)
TW 202229540A · 2022 [cited by applicant]
Thomalla M., et al., “Evidence of an antiinflammatory toll-like receptor 9 (TLR 9) pathway in adipocytes,” Journal of Endocrinology, vol. 240(2), 2019, p. 325-343. [cited by applicant]
Nihashi Y., et al., “Identification of a Novel Osteogenetic Oligodeoxynucleotide (osteoDN) That Promotes Osteoblast Differentiation in a TLR9-Independent Manner,” Nanomaterials, vol. 12(10), 2022, 1680, https://doi.org/… [cited by applicant]